First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Autor: Richard P. Baum, Helmut R. Mäcke, Jingjing Zhang, Dirk Müller, Christiane Schuchardt

Publikováno v: J Nucl Med

The objective of this study was to assess the safety, dosimetry, and efficacy of the (177)Lu-labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH(2) ((177)Lu-DOTA-LM3) in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67119a57e8f0b1f808a677867698415d
https://doi.org/10.2967/jnumed.120.258889

Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer

Autor: Lucia Baratto, Heying Duan, Helmut R. Mäcke, Andrei Iagaru

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(6)

Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic, or both diagnostic and therapeutic (theragnostic) purposes is a promising approach in oncologic applications. Such approaches have increased significantly over

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2478c23e0dd1ce3c88d74036abe2c387
https://pubmed.ncbi.nlm.nih.gov/32060215

Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P—results from a phase I study

Autor: Helmut R. Mäcke, Dominik Cordier, Adrian Merlo, Martin Sailer, Stefan Kneifel, Jan Müller-Brand, Luigi Mariani, Flavio Forrer

Complete surgical resection beyond tumor margins cannot be achieved in glioblastoma multiforme (GBM) because of infiltrative nature. In several cancers, neoadjuvant treatment has been implemented to reduce the risk of tumor cell spreading during rese

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a719f9f9a8e0516a39ca568f811dcf
http://doc.rero.ch/record/310762/files/11060_2010_Article_153.pdf

Towards Tailored Radiopeptide Therapy

Autor: Martin A. Walter, Piotr Radojewski, Jan Müller-Brand, Matthias Briel, Philippe Brunner, Rebecca A. Dumont, Nicolas Marincek, Helmut R. Mäcke

Publikováno v: Eur J Nucl Med Mol Imaging
Radojewski, Piotr; Dumont, Rebecca; Marincek, Nicolas; Brunner, Philippe; Mäcke, Helmut R; Müller-Brand, Jan; Briel, Matthias; Walter, Martin Alexander (2015). Towards tailored radiopeptide therapy. European journal of nuclear medicine and molecular imaging, 42(8), pp. 1231-1237. Springer 10.1007/s00259-015-3030-9

PURPOSE Somatostatin receptor-targeted radiopeptide therapy is commonly performed using single radioisotopes. We evaluated the benefits and harms of combining radioisotopes in radiopeptide therapy in patients with neuroendocrine tumor. METHODS Using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d4f82a381ab2524f1b4fa52b997609

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers

Autor: Helmut R. Mäcke, Beatrice Waser, Jean Rivier, Jean Claude Reubi

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 58(2)

There is recent in vitro and in vivo evidence that somatostatin receptor sst2 antagonists are better tools to target neuroendocrine tumors (NET) than sst2 agonists. Indeed, antagonists bind to a greater number of sst2 sites than agonists. Whether sst

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe87e89e69a0a81623787d3c9890e369
https://pubmed.ncbi.nlm.nih.gov/28818985